

Syrian Arab Republic

Tuberculosis profile

Population 2015

19 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.021 (0.019–0.022)	0.11 (0.1–0.12)
Mortality (HIV+TB only)	0 (-)	0 (-)
Incidence (includes HIV+TB)	3.6 (2.8–4.6)	20 (15–25)
Incidence (HIV+TB only)		
Incidence (MDR/RR-TB)**	0.34 (0.21–0.47)	1.8 (1.1–2.5)

Estimated TB incidence by age and sex (thousands)*, 2015

	0-14 years	> 14 years	Total
Females	0.2 (0.091–0.3)	1.1 (0.63–1.7)	1.3 (0.72–2)
Males	0.22 (0.14–0.3)	2.1 (1.5–2.6)	2.3 (1.7–2.9)
Total	0.42 (0.29–0.55)	3.2 (2.7–3.7)	3.6 (2.8–4.6)

TB case notifications, 2015

Total cases notified	2 992
Total new and relapse	2 908
- % tested with rapid diagnostics at time of diagnosis	3%
- % with known HIV status	<1%
- % pulmonary	58%
- % bacteriologically confirmed among pulmonary	79%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015 80% (64–100)

TB patients facing catastrophic total costs

TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.01 (0–0.01)

TB/HIV care in new and relapse TB patients, 2015

	Number	(%)
Patients with known HIV-status who are HIV-positive	3	20%
- on antiretroviral therapy	3	100%

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			150 (100–200)
Estimated % of TB cases with MDR/RR-TB	8% (4.9–11)	18% (11–27)	
% notified tested for rifampicin resistance	9%	56%	339
MDR/RR-TB cases tested for resistance to second-line drugs			0
Laboratory-confirmed cases		MDR/RR-TB: 4, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 9, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2014	70%	3 390
Previously treated cases, excluding relapse, registered in 2014	69%	95
HIV-positive TB cases, all types, registered in 2014		
MDR/RR-TB cases started on second-line treatment in 2013	100%	2
XDR-TB cases started on second-line treatment in 2013		0

TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment

% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

TB financing, 2016

National TB budget (US\$ millions)


* Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history


**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)



Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




Incidence


Notified (new and relapse)

Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



New and relapse


Retreatment, excluding relapse

HIV-positive

MDR/RR-TB

XDR-TB

Total budget (US\$ millions)



Unfunded

Funded internationally

Funded domestically